Liu W, Chen R J
Department of Otolaryngology Head and Neck Surgery, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Mar 5;31(5):366-368. doi: 10.13201/j.issn.1001-1781.2017.05.009.
To study the clinical effect of mometasone furoate nasal spray combined with montelukast in the treatment of adenoid hypertrophy in children.One hundred and thirty eight cases with adenoid hypertrophy were randomly divided into two groups, 69 cases in each group; the control group were treated with mometasone furoate nasal spray alone; the observation group were treated with mometasone furoate combined with oral montelukast. Adenoid nasopharynx ratio (A/N), and the proportion of overall recurrence after treatment of nasal obstruction were compared, also with snoring, mouth breathing rate, life quality score before and after treatment in the two groups, and finally compared the clinical total effective ratio.Compared with before treatment, A/N of two groups of patients were significantly decreased, and the observation group decreased more significantly, the difference between the two groups was significant (< 0.05); nasal obstruction, snoring, mouth breathing rate of observation group were significantly lower than the control group, and the recurrence rate also lower than the control group, the difference was statistically significant (< 0.05). The quality of life scores, sleep disorder scores, physical status score and daily function score in the two groups were significantly decreased after treatment, and in observation group the three scores were decreased more significantly, the difference between the two groups was statistically significant (< 0.05). The total efficiency of the observation group was 94.1%, which was statistically higher than the control group (79.4%, < 0.05).The clinical efficacy of mometasone furoate nasal spray combined with montelukast in the treatment of adenoid hypertrophy in children is significant, which can effectively reduce the adenoid nasopharynx ratio, improve the symptoms of snoring, mouth breathing, nasal congestion, improve the quality of life of patients, and the effective ratio was higher than single drug treatment, which was worthy to apply on clinic.
探讨糠酸莫米松鼻喷雾剂联合孟鲁司特治疗儿童腺样体肥大的临床效果。将138例腺样体肥大患儿随机分为两组,每组69例;对照组单纯使用糠酸莫米松鼻喷雾剂治疗;观察组采用糠酸莫米松联合口服孟鲁司特治疗。比较两组治疗后腺样体鼻咽比值(A/N)、鼻塞治疗后总体复发比例,以及打鼾、张口呼吸发生率、治疗前后生活质量评分,最后比较临床总有效率。与治疗前比较,两组患儿A/N均显著降低,且观察组降低更显著,两组差异有统计学意义(<0.05);观察组鼻塞、打鼾、张口呼吸发生率均显著低于对照组,复发率也低于对照组,差异有统计学意义(<0.05)。两组治疗后生活质量评分、睡眠障碍评分、身体状况评分及日常功能评分均显著降低,且观察组三项评分降低更显著,两组差异有统计学意义(<0.05)。观察组总有效率为94.1%,显著高于对照组(79.4%,<0.05)。糠酸莫米松鼻喷雾剂联合孟鲁司特治疗儿童腺样体肥大临床疗效显著,可有效降低腺样体鼻咽比值,改善打鼾、张口呼吸、鼻塞症状,提高患者生活质量,有效率高于单药治疗,值得临床推广应用。